Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we regale you with mid-August delights from the EMA, ICER, and a federal appeals court. Hope you had a lovely weekend.